High short interest (\~18% of float, previously higher) + binary Oct 30 PDUFA for their lead DNA medicine.
**TLDR**
This is a classic high-short + defined binary catalyst setup on a micro-cap. The short thesis is “they never get a product and keep diluting.” The long/squeeze thesis is “INO-3107 clears the regulatory bar (or the path clarifies positively) and shorts have to cover into a low-float name that suddenly has a commercial story.”
Oct 30 is the date. Everything between now and then (late-cycle communications, any meeting outcomes on the accelerated pathway, cash updates) can move the stock sharply in either direction.
Not financial advice. Position sizing, risk management, and your own diligence matter here — this can go to zero just as easily as it can squeeze. DYOR.
**The setup**
Inovio (INO) is a micro-cap DNA medicines company (market cap recently \~$80M range, price near $1). Shares outstanding \~82M, float essentially the same. Short interest has been elevated: recent reports put it around 14.5–15M shares short (\~17.8–18.4% of float), with earlier 2026 prints in the high teens / approaching 20% territory and days-to-cover that have been elevated at times. That is meaningful short pressure on a name this size.
Shorts are betting the company stays a perpetual clinical-stage story that keeps diluting. The near-term binary can challenge that.
**The catalyst**
Lead candidate INO-3107 is a DNA immunotherapy for recurrent respiratory papillomatosis (RRP) — HPV-6/11-driven disease that causes repeated growth of papillomas in the airway, forcing patients into frequent surgeries.
• BLA accepted for review under the accelerated approval pathway.
• PDUFA target date: October 30, 2026.
• Mid-cycle review completed with no new significant issues raised; late-cycle review scheduled for Q3.
• There is an outstanding question from FDA about eligibility for the accelerated pathway (raised in the acceptance letter). The company has been working through that (assessment aid submitted, informal meeting process). They are not currently planning a traditional Phase 3 route.
• Phase 1/2 data showed a large majority of patients with meaningful reductions in surgeries (year-1 and further improvement in year-2 follow-up without additional dosing in many cases). Breakthrough Therapy and Orphan designations are in place.
This would be Inovio’s first potential commercial product if approved. Commercial prep is underway. Cash (post-April raise) was guided to support operations into Q1 2027, past the PDUFA.
Other pipeline notes (secondary): Partner ApolloBio reported positive Phase 3 topline for VGX-3100 in China; there are ongoing immuno-oncology collaborations (including GBM work).
**Why a squeeze is plausible here**
• Short float in the high teens on a low absolute float / micro-cap creates the mechanical conditions. A sharp move on positive regulatory news or even constructive updates forces covering into limited liquidity.
• Binary event is defined and relatively near (Oct 30). Biotech retail money tends to pile into these setups when the narrative shifts from “another dilution machine” to “possible approval + first revenue.”
• Price is low enough that retail can move size relatively easily if volume spikes.
• Historical short interest has already shown the ability to expand quickly when sentiment is negative.
**The real risks (don’t ignore these)**
• FDA could ultimately reject accelerated approval eligibility or require more data / a different path. That is the key overhang.
• Dilution history is real — share count has expanded substantially. More capital raises are possible if the timeline slips or launch costs hit.
• Competition exists in RRP (including an already-approved product). Cash burn continues. This is still a binary biotech with going-concern language in filings if financing dries up.
• Short interest can stay elevated or even rise further if the market prices in a no-go or delay.